Genmab A/S - Depositary Receipt (Common Stock)
US ˙ NasdaqGS ˙ US3723032062

SecurityGMAB / Genmab A/S - Depositary Receipt (Common Stock)
InstitutionFmr Llc
Latest Disclosed Ownership1,011,726 shares
Latest Disclosed Value $ 27,144,600
Fmr Llc reports 4.31% decrease in ownership of GMAB / Genmab A/S - Depositary Receipt (Common Stock)

On May 15, 2026 - Fmr Llc filed a 13F-HR form disclosing ownership of 1,011,726 shares of Genmab A/S - Depositary Receipt (Common Stock) (US:GMAB) valued at $27,144,609 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 1,057,340 shares of Genmab A/S - Depositary Receipt (Common Stock). This represents a change in shares of -4.31% during the quarter. The current value of the position is $25,019,984 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F GENMAB A SPONSORED ADS 372303206 1,011,726 -45,614 -4.31 27,145 -16.65 0.0003
2026-02-17 2025-12-31 13F GENMAB A SPONSORED ADS 372303206 1,057,340 -62,374 -5.57 32,566 -5.17 0.0017
2025-11-13 2025-09-30 13F GENMAB A SPONSORED ADS 372303206 1,119,714 439,181 64.53 34,342 144.26 0.0018
2025-08-14 2025-06-30 13F GENMAB A SPONSORED ADS 372303206 680,533 195,687 40.36 14,060 48.10 0.0008
2025-05-12 2025-03-31 13F GENMAB A SPONSORED ADS 372303206 484,846 -55,707 -10.31 9,493 -15.85 0.0006
2025-02-13 2024-12-31 13F GENMAB A SPONSORED ADS 372303206 540,553 262,359 94.31 11,281 66.34 0.0007
2024-11-13 2024-09-30 13F GENMAB A SPONSORED ADS 372303206 278,194 33,076 13.49 6,782 10.12 0.0004
2024-08-13 2024-06-30 13F GENMAB A SPONSORED ADS 372303206 245,118 -129,289 -34.53 6,160 -45.00 0.0004
2024-05-13 2024-03-31 13F GENMAB A SPONSORED ADS 372303206 374,407 106,902 39.96 11,199 31.48 0.0008
2024-02-13 2023-12-31 13F GENMAB A SPONSORED ADS 372303206 267,505 -154,932 -36.68 8,517 -42.84 0.0007
2023-11-13 2023-09-30 13F GENMAB A SPONSORED ADS 372303206 422,437 24,936 6.27 14,899 -1.39 0.0013
2023-08-11 2023-06-30 13F GENMAB A SPONSORED ADS 372303206 397,501 6,090 1.56 15,109 2.23 0.0013
2023-08-11 2023-03-31 13F/A-1 GENMAB A SPONSORED ADS 372303206 391,411 -60,248 -13.34 14,780 -22.79 0.0014
2023-05-11 2023-03-31 13F GENMAB A SPONSORED ADS 372303206 391,411 -60,248 14,780 0.0003
2023-02-13 2022-12-31 13F GENMAB A SPONSORED ADS 372303206 451,659 14,661 3.35 19,141 36.32 0.0019
2022-11-10 2022-09-30 13F GENMAB A SPONSORED ADS 372303206 436,998 191,071 77.69 14,041 75.73 0.0015
2022-08-12 2022-06-30 13F GENMAB A SPONSORED ADS 372303206 245,927 25,320 11.48 7,990 0.10 0.0008
2022-05-13 2022-03-31 13F GENMAB A SPONSORED ADS 372303206 220,607 67,258 43.86 7,982 31.59 0.0006
2022-02-14 2021-12-31 13F GENMAB A SPONSORED ADS 372303206 153,349 21,459 16.27 6,066 5.24 0.0004
2022-02-14 2021-09-30 13F/A-1 GENMAB A SPONSORED ADS 372303206 131,890 19,300 17.14 5,764 25.39 0.0005
2021-11-15 2021-09-30 13F GENMAB A SPONSORED ADS 372303206 131,890 19,300 5,764 0.0001
2021-08-13 2021-06-30 13F GENMAB A SPONSORED ADS 372303206 112,590 -59,812 -34.69 4,597 -18.78 0.0004
2021-05-14 2021-03-31 13F GENMAB A SPONSORED ADS 372303206 172,402 88,934 106.55 5,660 66.76 0.0005
2021-02-08 2020-12-31 13F GENMAB A SPONSORED ADS 372303206 83,468 -169,255 -66.97 3,394 -63.32 0.0003
2020-11-13 2020-09-30 13F GENMAB A SPONSORED ADS 372303206 252,723 235,503 1,367.61 9,252 1,484.25 0.0009
2020-08-24 2020-06-30 13F/A-1 GENMAB A SPONSORED ADS 372303206 17,220 8,589 99.51 584 219.13 0.0001
2020-08-13 2020-06-30 13F GENMAB A SPONSORED ADS 372303206 17,220 8,589 584 14.3472
2020-05-14 2020-03-31 13F GENMAB A SPONSORED ADS 372303206 8,631 3,906 82.67 183 72.64 0.0000
2020-02-07 2019-12-31 13F GENMAB A S SPONSORED ADS 372303206 4,725 2,858 153.08 106 178.95 0.0000
2019-11-13 2019-09-30 13F GENMAB A S SPONSORED ADS 372303206 1,867 1,867 38 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.